← Mechanisms of action
EPHA2
SINGLE PROTEINHomo sapiens
Preferred name: Ephrin type-A receptor 2 ChEMBL ↗
Linked proteins
Drugs acting on this target (15)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| sirna-epha2-dopc | Antisense inhibitor | experimental | Nucleic acid | EPHA2 antisense inhibitor |
| epha2 peptide | Immunity, active | experimental | Vaccine | EPHA2 immunity, active |
| e-sync t cells | Immunity, passive | experimental | Cell therapy | EPHA2 immunity, passive |
| epha2-targeted car-dcs | Immunity, passive | experimental | Cell therapy | EPHA2 immunity, passive |
| epha2-targeted car-t cells | Immunity, passive | experimental | Cell therapy | EPHA2 immunity, passive |
| kras-epha-2-car-dc | Immunity, passive | experimental | Cell therapy | EPHA2 immunity, passive |
| tp53-epha-2-car-dc | Immunity, passive | experimental | Cell therapy | EPHA2 immunity, passive |
| bt5528 | Inhibitor | experimental | Peptide | EPHA2 inhibitor |
| dasatinib (sprycel) | Inhibitor | approved | Small molecule | EPHA2 inhibitor |
| ds-8895a | Inhibitor | experimental | mAb | EPHA2 inhibitor |
| medi-547 | Inhibitor | experimental | mAb | EPHA2 inhibitor |
| mm-310 | Inhibitor | experimental | Small molecule | EPHA2 inhibitor |
| regorafenib (stivarga) | Inhibitor | approved | Small molecule | Ephrin type-A receptor 2 |
| sc-102 | Inhibitor | experimental | Peptide | EPHA2 inhibitor |
| 89zr-ds-8895a | Radiopharmaceutical | experimental | mAb | EPHA2 radiopharmaceutical |